# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Keybanc analyst Scott Schoenhaus maintains LifeMD (NASDAQ:LFMD) with a Overweight and lowers the price target from $12 to $10.
LifeMD, Inc. (NASDAQ:LFMD) today announced the launch of private health insurance acceptance for its virtual primary care servi...
Keybanc analyst Scott Schoenhaus initiates coverage on LifeMD (NASDAQ:LFMD) with a Overweight rating and announces Price Tar...
- SEC Filing
B. Riley Securities analyst William Woods reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $12 price target.